KPTI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

35.84M

+17.34%

-2.170

-39.72%

34.60M

+15.28%

-1.953

-29.48%

35.48M

-6.46%

-1.560

-63.89%

Estimates Revision

The market is revising Downward the revenue expectations for Karyopharm Therapeutics Inc. (KPTI) for FY2025, with the revenue forecasts being adjusted by -0.33% over the past three months. During the same period, the stock price has changed by 7.75%.

Revenue Estimates for FY2025

Revise Downward

-0.33%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+20.82%

In Past 3 Month

Stock Price

Go Up

+7.75%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast KPTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KPTI is 13.83 USD with a low forecast of 6.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 6.745

Low

6.00

Averages

13.83

High

21.00

Current: 6.745

Low

6.00

Averages

13.83

High

21.00

RBC Capital

Brian Abrahams

Outperform

NULL

downgrade

$30 -> $19

2025-11-04

Reason

RBC Capital

Brian Abrahams

Price Target

$30 -> $19

2025-11-04

downgrade

Outperform

NULL

Reason

RBC Capital analyst Brian Abrahams lowered the firm's price target on Karyopharm to $19 from $30 and keeps an Outperform rating on the shares. The company reported a solid quarter for Xpovio sales, while the reduction of financing overhangs, and MF timelines intact for March 2026 make for a favorable risk/reward setup, the analyst tells investors in a research note. RBC adds however that its reduced price target reflects the recent financing transactions.

Baird

Outperform -> NULL

downgrade

$42 -> $25

2025-08-12

Reason

Baird

Price Target

$42 -> $25

2025-08-12

downgrade

Outperform -> NULL

Reason

Baird lowered the firm's price target on Karyopharm to $25 from $42 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results which showed its MF Phase 3 enrollment is early complete.

H.C. Wainwright

Robert Burns

Buy -> Neutral

downgrade

2025-07-16

Reason

H.C. Wainwright

Robert Burns

Price Target

2025-07-16

downgrade

Buy -> Neutral

Reason

H.C. Wainwright analyst Robert Burns downgraded Karyopharm to Neutral from Buy without a price target. The firm has solvency concerns, saying the company's recent failure to raise capital raise is a "significant concern." H.C. Wainwright also also takes into account that the top-line results from the Phase 3 trial evaluating selinexor in JAKi-naive myelofibrosis are not expected until Q1 of 2026.

H.C. Wainwright

Robert Burns

initiated

$27

2025-07-11

Reason

H.C. Wainwright

Robert Burns

Price Target

$27

2025-07-11

initiated

Reason

H.C. Wainwright analyst Robert Burns assumed coverage of Karyopharm with a Buy rating and $27 price target. The firm believes the company's investigation into maintenance therapy for the solid tumor indication is "risk-mitigated." Karyopharmhas "several significant data catalysts" that could drive investor interest, the analyst tells investors in a research note.

Barclays

Overweight

maintain

$5 -> $10

2025-05-13

Reason

Barclays

Price Target

$5 -> $10

2025-05-13

maintain

Overweight

Reason

Barclays raised the firm's price target on Karyopharm to $10 from $5 and keeps an Overweight rating on the shares. The company's Q1 selinexor revenue of $21.1M was below consensus of $28.7M, but the key focus for investors is on pivotal myelofibrosis data in late 2025/early 2026, the analyst tells investors in a research note. The firm adjusted its model to account for the recent stock split.

Baird

Colleen Kusy

Outperform -> Outperform

downgrade

$54 -> $42

2025-05-13

Reason

Baird

Colleen Kusy

Price Target

$54 -> $42

2025-05-13

downgrade

Outperform -> Outperform

Reason

Baird analyst Colleen Kusy lowered the firm's price target on Karyopharm to $42 from $54 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where the company updated its pipeline progress.

Valuation Metrics

The current forward P/E ratio for Karyopharm Therapeutics Inc (KPTI.O) is -0.96, compared to its 5-year average forward P/E of -2.24. For a more detailed relative valuation and DCF analysis to assess Karyopharm Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.24

Current PE

-0.96

Overvalued PE

-0.70

Undervalued PE

-3.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.35

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.41

Undervalued EV/EBITDA

-4.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.25

Current PS

0.83

Overvalued PS

4.32

Undervalued PS

0.17

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

KPTI News & Events

Events Timeline

No data

News

2.0

12-08PRnewswire

Karyopharm to Host Virtual Fireside Chat on December 10, 2025

1.0

12-08Newsfilter

Karyopharm to Participate in Baird's Biotech Discovery Series on December 10

1.0

12-01PRnewswire

Karyopharm to Participate in Piper Sandler Healthcare Conference in New York

People Also Watch

Frequently Asked Questions

What is Karyopharm Therapeutics Inc (KPTI) stock price today?

The current price of KPTI is 6.745 USD — it has decreased -2.95 % in the last trading day.

What is Karyopharm Therapeutics Inc (KPTI)'s business?

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

What is the price predicton of KPTI Stock?

What is Karyopharm Therapeutics Inc (KPTI)'s revenue for the last quarter?

Karyopharm Therapeutics Inc revenue for the last quarter amounts to 44.04M USD, increased 13.57 % YoY.

What is Karyopharm Therapeutics Inc (KPTI)'s earnings per share (EPS) for the last quarter?

Karyopharm Therapeutics Inc. EPS for the last quarter amounts to -3.82 USD, decreased -0.78 % YoY.

What changes have occurred in the market's expectations for Karyopharm Therapeutics Inc (KPTI)'s fundamentals?

How many employees does Karyopharm Therapeutics Inc (KPTI). have?

Karyopharm Therapeutics Inc (KPTI) has 279 emplpoyees as of December 15 2025.

What is Karyopharm Therapeutics Inc (KPTI) market cap?

Today KPTI has the market capitalization of 118.50M USD.